Evidence map›Paper›PMID 36578495›Full record

ArticleFrontiers in immunology2022

Inhibition of the different complement pathways has varying impacts on the serum bactericidal activity and opsonophagocytosis against

Lukas Muri, Anna Schubart, Christine Thorburn, Natasa Zamurovic, Thomas Holbro, Michael Kammüller, Gerd Pluschke, Emma Ispasanie

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

Lukas MuriMolecular Immunology Unit, Swiss Tropical and Public Health Institute, Basel, Switzerland.
Anna SchubartDepartment Autoimmunity, Transplantation and Inflammation, Novartis Institutes for Biomedical Research, Basel, Switzerland.
Christine ThorburnNovartis Pharma AG, London, United Kingdom.
Natasa ZamurovicTranslational Medicine-Preclinical Safety, Novartis Institutes for Biomedical Research, Basel, Switzerland.
Thomas HolbroGlobal Drug Development, Novartis Pharma AG, Basel, Switzerland.
Michael KammüllerTranslational Medicine-Preclinical Safety, Novartis Institutes for Biomedical Research, Basel, Switzerland.
Gerd PluschkeMolecular Immunology Unit, Swiss Tropical and Public Health Institute, Basel, Switzerland.
Emma IspasanieMolecular Immunology Unit, Swiss Tropical and Public Health Institute, Basel, Switzerland.
Novartis (Switzerland) · CHUniversity of Basel · CHNovartis Institutes for BioMedical ResearchNovartis (United Kingdom) · GBSwiss Tropical and Public Health Institute · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Defense against

Indexed as

Haemophilus InfectionsHaemophilus influenzae type bAdultAntibodies, BacterialComplement System ProteinsHumansOpsonizationAntibodies, BacterialComplement System Proteinsalternative pathway (AP)complement inhibitorsHaemophilus influenzae type bimmunotherapyopsonophagocytosisserum bactericidal activity (SBA)vaccination

Identifiers

PMID36578495
PMCPMC9791579
OpenAlexW4312127167

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.